Ocular in situ gel: An overview
Abstract
Eye is the most sensitive organ of the body. Designing of ocular drug delivery system is the most challenging field for pharmaceutical scientists as less than 5% of administered drug enters the eye due to the complicated anatomical structure of the eye, small absorptive surface and low transparency of the cornea, lipophilicity of corneal epithelium, pre corneal loss (due to nasolacrimal drainage), bonding of the drug with proteins contained in tear fluid, blinking, low capacity of conjunctival sac, that restricts the entry of drug molecule at the site of action and ultimately leads to poor ocular therapy. To improve ophthalmic drug bioavailability, there are considerable efforts directed towards newer drug delivery systems for ophthalmic administration. These novel drug delivery systems offer manifold advantages over conventional systems as they increase the efficiency of drug delivery by improving the release profile and also reduce drug toxicity. A lot of research going on in this area proves the fact that in situ gelling systems can be beneficial in the ocular drug delivery. In situ gel forming systems are drug delivery systems that are in solution form before administration in the body but once administered, undergo in situ gelation, to form a gel triggered by external stimulus such as temperature, pH etc. This review is to Specify a brief summary about in situ gels, various approaches for in situ gelling systems, different types of polymers used in in situ gels, their mechanisms of gel formation and evaluation of polymeric in situ gel.
Keywords: in situ gel, polymers, Temperature induced in situ gel system, pH induced in situ gel system, Ion activated systems.
Downloads
Download data is not yet available.
References
1. AH EL-Kamel. In vitro and in vivo evaluation of Pluronic F127- based ocular delivery system for timolol maleate. International journal of pharmaceutics 2002; 24 (1): 47–55.
2. Varshosaz J, Tabbakhian M, Salmani Z. Designing of a Thermo sensitive Chitosan/Poloxamer In Situ Gel for Ocular Delivery of Ciprofloxacin. The Open Drug Delivery Journal 2008; 2: 61-70.
3. Nalla A and Chinnala KM. In - situ ophthalmic drug delivery systems – An Overview , Indo Am. J. Pharm. Sci. 2016; 3(3): 202-208.
4. NA Peppas, R Langer. New challenges in biomaterials. Science 1994; 263(5154): 1715-1720.
5. Swapnil S. A review on polymers used in novel in situ gel formulation for ocular drug delivery and their evaluation. Journal of biological and scientific opinion 2003; 1(2): 132-137.
6. Hajare A et al. A rational approach to ocular drug delivery systems: A overview. World journal of pharmaceutical research 2014; 3(2): 3324- 3348.
7. Bucolo C, Drago F and Salomone S. Ocular drug delivery: a clue from nanotechnology. Frontiers in Pharmacology 2012:3; 1-3.
8. Mali MN, Hajare AA. In-situ gel forming systems for sustained ocular drug delivery system. European Industrial Pharmacy 2010; 5: 17-20.
9. Patil RN,Kumar RS. In-situ gelling system: Novel approach for ophthalmic drug delivery. World Journal of Pharmacy and Pharmaceutical Sciences 2014; 3(7): 423- 440.
10. Patil Rajeshwari N, Kumar Rachana S. In-situ gelling system: Novel approach for ophthalmic drug delivery.World Journal of Pharmacy and Pharmaceutical Sciences 2014; 3(7): 423-440.
11. Parekh HB, Rishad J, Jivani NP, Patel LD, Makwana A, Sameja K. Novel In situ polymeric drug delivery system: A Review. J. Drug Deliv. & Therap. 2012; 2(5):136-145.
12. Nirmal HB, Bakliwal SR, Pawar SP. In Situ Gel: New trends in controlled and sustained drug delivery system. Int. J. Pharm.Tech. Res. 2010; 2(2):1398-1408.
13. Nerkar TS, Gujarathi NA, Bhushan R, Bakliwal SR, Pawar SP. In situ Gel: Novel Approach in Sustained and Controlled DrugDelivery System, Pharma. Sci. monitor 2013; 4(4):1-18.
14. Kulkarni Vishakha S,Butte Kishore D,Rathod Sudha S.Natural polymers: a comprehensive review. International Journal of Research in Pharmaceutical and Biomedical Sciences 2012; 3(4): 1597-1613.
15. Suryawanshi Sarika S, Kunjwani HK, Kawade JV, Alkunte MA, Yadav DJ. Novel polymeric in situ gels for Ophthalmic drug delivery system. International Journal of Research in Pharmacy and Science 2012; 2(1): 67-83.
16. Rowe,Sheskey,Owen.Handbook of Pharmaceutical Excipients. Fifth edition. Published by the Pharmaceutical Press., 2006.
17. Tinu TS,Thomas Litha,Kumar Anil B.Polymers used in ophthalmic in-situ gelling system. International Journal of Pharmaceutical Sciences Review and Research 2013; 20(1): 176-183.
18. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. Journal of Controlled Release 2007; 122: 119-134
19. Boddeda Bhavani,Ratna Vijaya J,Battu Heera.A review on Mucoadhesive polymers in ophthalmics. International Journal of Pharmaceutical Sciences Review and Research 2014; 24(1): 237-245.
20. Katariya Dhirajkumar Champalal,Poddar Sushilkumar S.Current status of ophthalmic in situ forming hydrogel. International Journal of Pharma and Bio Sciences 2012; 3(3): 372-388.
21. Kamel S, Ali N, Jahangir K, Shah SM,El-Gendy AA. Pharmaceutical significance of cellulose: A review.Express Polymer Letters., 2008; 2(11): 758-778.
22. Ghosal Kajal,Chakraborty Subrata,Nanda Arunabha.Hydroxypropylmethylcellulose in drug delivery. Pelagia Research Library,Der Pharmacia Sinica. 2011; 2(2): 152-168.
23.Gambhire Savita,Bhalerao Karuna,Singh Sushma.In-situ hydrogel:different approaches to ocular drug delivery.International Journal of Pharmacy and Pharmaceutical Sciences 2013; 5(2): 27-36
24. Balasingam R, Khan A, Thinakaran R. Formulation of in situ gelling systems for ophthalmic delivery of erythromycin. International journal of students research in technology and management 2017; 5(3): 01-08.
25. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release 2007; 122(2): 119-134.
26.Cao Y, Zhang C, Shen W, Cheng Z, Yu L, et al. Poly (N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J Control Rel. 2007; 120(3): 186- 194.
27. Meshram S, Thorat S. Ocular in Situ gels: Development, evaluation and advancements. Sch Acad J Pharm. 2015; 4(7): 340-346.
28. Ma WD, Xu H, Wang C, Nie SF, Pan WS. Pluronic F127-g-poly (acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Pharm. 2008; 350(1-2): 247-256.
29. Jain D, Kumar V, Singh S, Mullertz A, Bar-Shalom D. Newer trends in in Situ gelling systems for controlled ocular drug delivery. J Anal Pharm Res. 2016; 2(3): 00022.
30. Kumar D, Jain N, Gulati N, Nagaich U. Nanoparticles laden in situ gelling system for ocular drug targeting. J Adv Pharm Technol Res. 2013; 4(1): 9-17.
31. Darwhekar G, Jain P, Jain DK et al. Devlopment and optimization of Dorzolamide HCl and Timolol Maleate in situ gel for glaucoma treatment. Asian J Pharm An. 2011; 1: 93-97.
32. Pawar SD, Pawar RG, Gadhve MV et al. Controlled release in situ forming gatifloxacine HCl for ophthalmic drug delivery. Int Res J of Phar. 2012; 3: 86-89.
33. Rathore KS. In situ gelling ophthalmic drug delivery system: an overview. Int J Pharm Sci Res. 2010; 2:30-34.
34. Patel HA, Patel JK, Patel KN et al. Ophthalmic drug delivery system- a review. Sch Res Lib. 2010; 2: 100-115.
35. Avis KE, Liberman HA, Lachman L. Pharmaceutical dosage forms- Parentral medication. Marcel Dekker, Inc.1993.
36. Singh V, Bushetti SS, Raju SA, et al. Glaucoma: A treatment by hydrogel. An Int J Pharm Sci. 2011; 2: 174-183.
37. Geethalakshmi A, Karki R, Sagi P et al. Temperature triggered in situ gelling systems for Betoxolol in glaucoma. J Appl Pharm Sci. 2013; 3:153-159.
38. Basaran B, Bozkir A. Thermosensitive and pH induced in situ ophthalmic gelling system for ciprofloxacin hydrochloride: hydroxypropyl cyclodextrin complex. Acta Poloniae Pharm Drug Res. 2012; 69: 6: 1137-1147.
39. Patil AP, Tagalpallewar AA, Rasve GM et al. A novel ophthalmic drug delivery systems: in situ gel. Int J Pharm Sci Res. 2012; 3: 2938-2946.
40. Mudgil M, Pawar PK. Preparation and in vitro/ex vivo evaluation of Moxifloxacin loaded PLGA nanosuspension for ophthalmic application. Sci Pharmaceutica 2013; 81: 591-606.
41. Vodithala S et al. Formulation and evaluation of ion activated ocular gels of Ketorolac Tromethamine. Int J of Current Pharm Res. 2010; 2: 33-38.
42. Jain GK, Pathan SA, Akhter S. Microscopic and spectroscopic evaluation of novel PLGA-chitosan nanoplexes as an ocular delivery systems. Colloids and Surface B 2011; 82: 397-403.
43. Deshmukh G et al. Evaluation of eye irritation potential of aqueous leaf extract of Achyranthes aspera by in vitro and in vivo method. Int Schol Res Network 2012; 1-5.
44. Heppenheimer A et al. Comparative evaluation of cosmetic formulation with different alternative methods for eye irritation. Japanese Society for Alternatives to Animal Experiments 2007; 505-507.
45. Urtti A, Pipkin J, Rork G, Repta A: Controlled drug delivery devices for experimental ocular studies with timolol in vitro release studies, International Journal of Pharmaceutics 1990; 61: 235-240.
46. Annex to the ICH Harmonised Tripartite Guidelines on stability testing of new drug substances and products. Q1A (R2) 2003.
47. Kute PR, Gondkar SB, Saudagar RB. Ophthalmic in-situ gel: an overview. World J Pharmacy Pharm Science 2015; 4: 549-568.
2. Varshosaz J, Tabbakhian M, Salmani Z. Designing of a Thermo sensitive Chitosan/Poloxamer In Situ Gel for Ocular Delivery of Ciprofloxacin. The Open Drug Delivery Journal 2008; 2: 61-70.
3. Nalla A and Chinnala KM. In - situ ophthalmic drug delivery systems – An Overview , Indo Am. J. Pharm. Sci. 2016; 3(3): 202-208.
4. NA Peppas, R Langer. New challenges in biomaterials. Science 1994; 263(5154): 1715-1720.
5. Swapnil S. A review on polymers used in novel in situ gel formulation for ocular drug delivery and their evaluation. Journal of biological and scientific opinion 2003; 1(2): 132-137.
6. Hajare A et al. A rational approach to ocular drug delivery systems: A overview. World journal of pharmaceutical research 2014; 3(2): 3324- 3348.
7. Bucolo C, Drago F and Salomone S. Ocular drug delivery: a clue from nanotechnology. Frontiers in Pharmacology 2012:3; 1-3.
8. Mali MN, Hajare AA. In-situ gel forming systems for sustained ocular drug delivery system. European Industrial Pharmacy 2010; 5: 17-20.
9. Patil RN,Kumar RS. In-situ gelling system: Novel approach for ophthalmic drug delivery. World Journal of Pharmacy and Pharmaceutical Sciences 2014; 3(7): 423- 440.
10. Patil Rajeshwari N, Kumar Rachana S. In-situ gelling system: Novel approach for ophthalmic drug delivery.World Journal of Pharmacy and Pharmaceutical Sciences 2014; 3(7): 423-440.
11. Parekh HB, Rishad J, Jivani NP, Patel LD, Makwana A, Sameja K. Novel In situ polymeric drug delivery system: A Review. J. Drug Deliv. & Therap. 2012; 2(5):136-145.
12. Nirmal HB, Bakliwal SR, Pawar SP. In Situ Gel: New trends in controlled and sustained drug delivery system. Int. J. Pharm.Tech. Res. 2010; 2(2):1398-1408.
13. Nerkar TS, Gujarathi NA, Bhushan R, Bakliwal SR, Pawar SP. In situ Gel: Novel Approach in Sustained and Controlled DrugDelivery System, Pharma. Sci. monitor 2013; 4(4):1-18.
14. Kulkarni Vishakha S,Butte Kishore D,Rathod Sudha S.Natural polymers: a comprehensive review. International Journal of Research in Pharmaceutical and Biomedical Sciences 2012; 3(4): 1597-1613.
15. Suryawanshi Sarika S, Kunjwani HK, Kawade JV, Alkunte MA, Yadav DJ. Novel polymeric in situ gels for Ophthalmic drug delivery system. International Journal of Research in Pharmacy and Science 2012; 2(1): 67-83.
16. Rowe,Sheskey,Owen.Handbook of Pharmaceutical Excipients. Fifth edition. Published by the Pharmaceutical Press., 2006.
17. Tinu TS,Thomas Litha,Kumar Anil B.Polymers used in ophthalmic in-situ gelling system. International Journal of Pharmaceutical Sciences Review and Research 2013; 20(1): 176-183.
18. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. Journal of Controlled Release 2007; 122: 119-134
19. Boddeda Bhavani,Ratna Vijaya J,Battu Heera.A review on Mucoadhesive polymers in ophthalmics. International Journal of Pharmaceutical Sciences Review and Research 2014; 24(1): 237-245.
20. Katariya Dhirajkumar Champalal,Poddar Sushilkumar S.Current status of ophthalmic in situ forming hydrogel. International Journal of Pharma and Bio Sciences 2012; 3(3): 372-388.
21. Kamel S, Ali N, Jahangir K, Shah SM,El-Gendy AA. Pharmaceutical significance of cellulose: A review.Express Polymer Letters., 2008; 2(11): 758-778.
22. Ghosal Kajal,Chakraborty Subrata,Nanda Arunabha.Hydroxypropylmethylcellulose in drug delivery. Pelagia Research Library,Der Pharmacia Sinica. 2011; 2(2): 152-168.
23.Gambhire Savita,Bhalerao Karuna,Singh Sushma.In-situ hydrogel:different approaches to ocular drug delivery.International Journal of Pharmacy and Pharmaceutical Sciences 2013; 5(2): 27-36
24. Balasingam R, Khan A, Thinakaran R. Formulation of in situ gelling systems for ophthalmic delivery of erythromycin. International journal of students research in technology and management 2017; 5(3): 01-08.
25. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release 2007; 122(2): 119-134.
26.Cao Y, Zhang C, Shen W, Cheng Z, Yu L, et al. Poly (N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. J Control Rel. 2007; 120(3): 186- 194.
27. Meshram S, Thorat S. Ocular in Situ gels: Development, evaluation and advancements. Sch Acad J Pharm. 2015; 4(7): 340-346.
28. Ma WD, Xu H, Wang C, Nie SF, Pan WS. Pluronic F127-g-poly (acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Pharm. 2008; 350(1-2): 247-256.
29. Jain D, Kumar V, Singh S, Mullertz A, Bar-Shalom D. Newer trends in in Situ gelling systems for controlled ocular drug delivery. J Anal Pharm Res. 2016; 2(3): 00022.
30. Kumar D, Jain N, Gulati N, Nagaich U. Nanoparticles laden in situ gelling system for ocular drug targeting. J Adv Pharm Technol Res. 2013; 4(1): 9-17.
31. Darwhekar G, Jain P, Jain DK et al. Devlopment and optimization of Dorzolamide HCl and Timolol Maleate in situ gel for glaucoma treatment. Asian J Pharm An. 2011; 1: 93-97.
32. Pawar SD, Pawar RG, Gadhve MV et al. Controlled release in situ forming gatifloxacine HCl for ophthalmic drug delivery. Int Res J of Phar. 2012; 3: 86-89.
33. Rathore KS. In situ gelling ophthalmic drug delivery system: an overview. Int J Pharm Sci Res. 2010; 2:30-34.
34. Patel HA, Patel JK, Patel KN et al. Ophthalmic drug delivery system- a review. Sch Res Lib. 2010; 2: 100-115.
35. Avis KE, Liberman HA, Lachman L. Pharmaceutical dosage forms- Parentral medication. Marcel Dekker, Inc.1993.
36. Singh V, Bushetti SS, Raju SA, et al. Glaucoma: A treatment by hydrogel. An Int J Pharm Sci. 2011; 2: 174-183.
37. Geethalakshmi A, Karki R, Sagi P et al. Temperature triggered in situ gelling systems for Betoxolol in glaucoma. J Appl Pharm Sci. 2013; 3:153-159.
38. Basaran B, Bozkir A. Thermosensitive and pH induced in situ ophthalmic gelling system for ciprofloxacin hydrochloride: hydroxypropyl cyclodextrin complex. Acta Poloniae Pharm Drug Res. 2012; 69: 6: 1137-1147.
39. Patil AP, Tagalpallewar AA, Rasve GM et al. A novel ophthalmic drug delivery systems: in situ gel. Int J Pharm Sci Res. 2012; 3: 2938-2946.
40. Mudgil M, Pawar PK. Preparation and in vitro/ex vivo evaluation of Moxifloxacin loaded PLGA nanosuspension for ophthalmic application. Sci Pharmaceutica 2013; 81: 591-606.
41. Vodithala S et al. Formulation and evaluation of ion activated ocular gels of Ketorolac Tromethamine. Int J of Current Pharm Res. 2010; 2: 33-38.
42. Jain GK, Pathan SA, Akhter S. Microscopic and spectroscopic evaluation of novel PLGA-chitosan nanoplexes as an ocular delivery systems. Colloids and Surface B 2011; 82: 397-403.
43. Deshmukh G et al. Evaluation of eye irritation potential of aqueous leaf extract of Achyranthes aspera by in vitro and in vivo method. Int Schol Res Network 2012; 1-5.
44. Heppenheimer A et al. Comparative evaluation of cosmetic formulation with different alternative methods for eye irritation. Japanese Society for Alternatives to Animal Experiments 2007; 505-507.
45. Urtti A, Pipkin J, Rork G, Repta A: Controlled drug delivery devices for experimental ocular studies with timolol in vitro release studies, International Journal of Pharmaceutics 1990; 61: 235-240.
46. Annex to the ICH Harmonised Tripartite Guidelines on stability testing of new drug substances and products. Q1A (R2) 2003.
47. Kute PR, Gondkar SB, Saudagar RB. Ophthalmic in-situ gel: an overview. World J Pharmacy Pharm Science 2015; 4: 549-568.
Crossmark
Statistics
4561 Views | 2497 Downloads
How to Cite
1.
Majeed A, Khan NA. Ocular in situ gel: An overview. JDDT [Internet]. 15Jan.2019 [cited 18Apr.2024];9(1):337-4. Available from: https://www.jddtonline.info/index.php/jddt/article/view/2231
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.